Ribonucleic Acid (RNA) Therapy Clinical Trials Market Outlook Highlights The Next Major Growth Opportunities
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Ribonucleic Acid (RNA) Therapy Clinical Trials Market Expansion Outlook: What Revenue Opportunities Lie Ahead?
The ribonucleic acid (rna) therapy clinical trials market has experienced consistent expansion in recent years, with projections indicating it will increase from $2.7 billion in 2025 to $2.83 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.8%. This past growth can be accounted for by a scarcity of rna-based treatment options, the substantial expenses associated with early-stage clinical trials, difficulties in securing regulatory approvals, limited awareness of rna therapies, and a continued dependence on conventional therapeutic approaches.
Over the coming years, steady growth is projected for the market focused on ribonucleic acid (RNA) therapy clinical trials. By 2030, the market is anticipated to reach $3.4 billion, reflecting a compound annual growth rate (CAGR) of 4.7%. Several factors are expected to fuel this expansion during the forecast period, including improvements in RNA delivery technologies, heightened investment in rare disease and anticancer research, strengthened collaborations between biotechnology and pharmaceutical firms, a growing emphasis on personalized medicine, and an increase in global clinical trial networks. Key trends likely to shape this period involve a rising number of RNA therapy clinical trials spanning diverse therapeutic fields, intensified efforts on rare disease and anticancer RNA therapeutics, an uptick in mRNA vaccine and self-amplifying RNA therapy trials, the emergence of CRISPR and RNA editing-based therapy trials, and the incorporation of advanced delivery platforms alongside oligonucleotide conjugates.
Download A Free Sample Report For Comprehensive Market Insights:
Ribonucleic Acid (RNA) Therapy Clinical Trials Market Growth Drivers: What Factors Are Accelerating Expansion?
The anticipated expansion of the ribonucleic acid (RNA) therapy clinical trials market will be driven by the growing weight of infectious diseases. These diseases stem from pathogenic microorganisms such as bacteria, viruses, fungi, or parasites that infiltrate the body, multiply, and disrupt normal functions. A primary factor behind the surge in infectious diseases is the increase in international travel, which accelerates the dissemination of pathogens across various regions and communities. By facilitating the creation and assessment of targeted therapies capable of swiftly adapting to new pathogens, RNA therapy clinical trials play a vital role in combating these illnesses. For example, the Minnesota Department of Health, a state agency in the US, reported in April 2025 that the proportion of HIV cases among males aged 35 to 39 climbed from 10% in 2023 to 17% in 2024. Consequently, the rising prevalence of infectious diseases is fueling growth within the RNA therapy clinical trials market.
Ribonucleic Acid (RNA) Therapy Clinical Trials Market Segment Landscape: Which Areas Lead Market Development?
The ribonucleic acid (rna) therapy clinical trials market covered in this report is segmented –
1) By Modality: Ribonucleic Acid (RNA) Interference, Antisense Therapy, Messenger Ribonucleic Acid (RNA), Oligonucleotide, Non-Antisense, Non-Ribonucleic Acid Interference (RNAi)
2) By Clinical Trials Phase: Phase I, Phase II, Phase III, Phase IV
3) By Therapeutic Areas: Rare Diseases, Anti-Infective, Anticancer, Neurological, Alimentary Or Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas
Subsegments:
1) By Ribonucleic Acid (RNA) Interference: Small Interfering RNA (siRNA) Therapy Trials, MicroRNA (miRNA)-Based Therapy Trials, Short Hairpin RNA (shRNA) Therapy Trials, Dicer Substrate RNA Therapy Trials
2) By Antisense Therapy: Gapmer Antisense Oligonucleotide Trials, Steric Blocking Antisense Trials, Splice-Switching Antisense Oligonucleotide Trials, Antisense Oligonucleotide-Conjugated Delivery Trials
3) By Messenger Ribonucleic Acid (RNA): mRNA-Based Vaccines Trials, Self-Amplifying mRNA (saRNA) Therapy Trials, Non-Replicating mRNA Therapy Trials, Circular mRNA Therapy Trials
4) By Oligonucleotide: Phosphorothioate Oligonucleotide Trials, Peptide Nucleic Acid (PNA) Trials, Locked Nucleic Acid (LNA) Trials, Morpholino Oligonucleotide Trials
5) By Non-Antisense: RNA Aptamer Therapy Trials, Guide RNA (gRNA)-Mediated CRISPR Trials, RNA Editing Therapy Trials, RNA Scaffolding Or Regulatory RNA Therapy Trials
6) By Non-Ribonucleic Acid Interference (RNAi): Ribozymes Therapy Trials, RNA Decoys Or Sponge RNA Trials, Long Non-Coding RNA (lncRNA) Therapy Trials, Small Activating RNA (saRNA) Therapy Trials
Ribonucleic Acid (RNA) Therapy Clinical Trials Market Trends: What Is Shaping Future Industry Growth?
Key players in the RNA therapy clinical trials market are concentrating on advancing breakthrough approaches, including antisense oligonucleotide therapies based on RNA, designed to bind particular genetic sequences, regulate gene expression, and deliver extremely accurate treatments for genetic and rare conditions. An RNA-driven antisense oligonucleotide clinical trial examines how brief synthetic RNA molecules attach to specific messenger RNA targets, aiming to control gene activity and address genetic disorders. As an example, Sepul Bio, a biotechnology firm based in France, launched in December 2024 the LUNA Phase 2b clinical study assessing ultevursen, an RNA-based antisense oligonucleotide therapy focused on mutations in exon 13 of the USH2A gene responsible for retinitis pigmentosa (RP) and Usher syndrome type 2a. This randomized, double-masked, sham-controlled trial, spanning two years, will involve 81 participants—adults and children aged eight and older—recruited from various global sites. The treatment is designed for individuals suffering from RP or non-syndromic RP linked to exon 13 mutations in USH2A, confirmed via genetic testing. Building on encouraging outcomes from earlier Phase 1/2 trials, where ultevursen demonstrated improvements in visual clarity, retinal sensitivity, and retinal architecture, the LUNA study advances this research.
Ribonucleic Acid (RNA) Therapy Clinical Trials Market Industry Leaders And Market Competition
Major companies operating in the ribonucleic acid (rna) therapy clinical trials market are Pfizer Inc., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Moderna Inc., BioNTech SE, Biogen Inc., Daiichi Sankyo Company Limited, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Cartesian Therapeutics Inc., CureVac N.V., Orna Therapeutics Inc., Silence Therapeutics plc, ETHRIS GmbH, ProQR Therapeutics N.V., Lexeo Therapeutics Inc., Avidity Biosciences Inc., Aro Biotherapeutics Company, Wave Life Sciences Ltd.
Access The Complete Ribonucleic Acid (RNA) Therapy Clinical Trials Market Report:
Ribonucleic Acid (RNA) Therapy Clinical Trials Market Geographic Distribution And Regional Opportunities
North America was the largest region in the ribonucleic acid (RNA) therapy clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ribonucleic acid (rna) therapy clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
